| Property | Value |
|---|
|
?:abstract
|
-
To address coronavirus disease (COVID-19), currently, no effective drug or vaccine is available. In this regard, molecular modeling approaches are highly useful to discover potential inhibitors of the main protease (M(pro)) enzyme of SARS-CoV-2. Since, the M(pro) enzyme plays key roles in mediating viral replication and transcription; therefore, it is considered as an attractive drug target to control SARS-CoV-2 infection. By using structure-based drug design, pharmacophore modeling, and virtual high throughput drug screening combined with docking and all-atom molecular dynamics simulation approach, we have identified five potential inhibitors of SARS-CoV-2 M(pro). MD simulation studies revealed that compound 54035018 binds to the M(pro) with high affinity (ΔG(bind) −37.40 kcal/mol), and the complex is more stable in comparison with other protein-ligand complexes. We have identified promising leads to fight COVID-19 infection as these compounds fulfill all drug-likeness properties. However, experimental and clinical validations are required for COVID-19 therapy. Communicated by Ramaswamy H. Sarma
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
-
10.1080/07391102.2020.1848634
|
|
?:doi
|
|
|
?:journal
|
-
Journal_of_biomolecular_structure_&_dynamics
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/b9f7fbaaa20ff595853d9ded9183f50ed52a81b9.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7682383.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Structure-based identification of potential SARS-CoV-2 main protease inhibitors
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}